Jack A. Khattar - Sep 3, 2024 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Sep 3, 2024
Transactions value $
-$350,571
Form type
4
Date filed
9/3/2024, 05:00 PM
Previous filing
Aug 27, 2024
Next filing
Nov 8, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $0 +21K +2.29% $0.00 936K Sep 3, 2024 Direct F1
transaction SUPN Common Stock Tax liability -$351K -10K -1.07% $34.90 926K Sep 3, 2024 Direct F2
holding SUPN Common Stock 1.02M Sep 3, 2024 By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Performance Share Unit Options Exercise $0 -21K -100% $0.00 0 Sep 3, 2024 Common Stock 21K $0.00 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023.
F2 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3 On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.